Table 1 |
||||
| Patient characteristics and outcome | ||||
| Variable | All | Malignant | Benign | P |
| (n =70) | (n = 58) | (n = 12) | ||
| Age in years,median(IQR) | 59(48–67) | 61(52–69) | 43 (35–52) | <0.001c |
| Age group, n (%) | 0.002b | |||
| <65 years | 42 (60) | 30 (52) | 12 (100) | |
| 65 years | 28 (40) | 28 (48) | 0 (0) | |
| Sex,n(%) | 0.011a | |||
| Male | 35 (50) | 33 (57) | 2 (17) | |
| Female | 35 (50) | 25 (43) | 10 (83) | |
| ASA physical status, n (%) | <0.001a | |||
| I/II | 23 (33) | 11 (19) | 12 (100) | |
| III/IV | 47 (67) | 47 (81) | 0 (0) | |
| Body Mass Index in Kg/m2, median (IQR) | 25 (22–30) | 26 (23–30) | 22 (21–30) | 0.163b |
| Type of anesthesia, n (%) | 0.440a | |||
| General | 59 (84) | 48 (83) | 11 (92) | |
| Combined general locorregional | 11 (16) | 10 (17) | 1(8) | |
| Duration of anesthesia (minutes), median (IQR) | 300 (268–360) | 300 (270–360) | 285 (245–315) | 0.298b |
| Intraoperative fluid volume | ||||
| Crystalloids (L.), median (P25–P75) | 4.0 (3.2 – 4.9) | 4.0 (3.3 – 4.9) | 3.0 (3.0 – 5.2) | 0.174b |
| Colloids (L.), median (P25–P75) | 0.5 (0 – 0.5) | 0.5 (0 – 0.5) | 0 (0 – 0.4) | 0.083b |
| Erythrocytes (Unit), median (P25–P75) | 0 (0 – 1.0) | 0 (0 – 1.0) | 0 (0 – 0.0) | 0.163b |
| Fresh Frozen plasma (Unit), median (P25–P75) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.295b |
| Platelets (Unit), median (P25–P75) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.517b |
| Temperature at PACU admission (°C), median (IQR) | 34.7 (33.9–35.5) | 34.8 (33.9–35.6) | 34.7 (33.5–35.2) | 0.623b |
| Hypertension,n (%) | 37(53) | 35(60) | 2(17) | 0.006a |
| Hyperlipidemia,n (%) | 25(36) | 24(41) | 1(8) | 0.030a |
| Pulmonary obstructive disease, n (%) | 8 (11) | 8 (14) | 0 (0) | 0.172a |
| Ischemic heart disease, n (%) | 6 (9) | 6 (10) | 0 (0) | 0.244a |
| Congestive heart disease, n (%) | 10 (14) | 10 (17) | 0 (0) | 0.132a |
| Cerebrovascular disease, n (%) | 3 (4) | 3 (5) | 0 (0) | 0.778a |
| Renal insufficiency, n (%) | 4 (6) | 3(5) | 1 (8) | 0.668a |
| Insulin therapy for diabetes, n (%) | 3 (4) | 3(5) | 0 (0) | 0.421a |
| Total RCRI, n (%) | 0.349a | |||
| ≤2 | 66 (94) | 54 (93) | 12 (100) | |
| >2 | 4 (6) | 4 (7) | 0 (0) | |
| Katz scale, median (IQR) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.424b |
| Dependency in I-ADL, n (%) | 3 (4) | 3 (5) | 0 (0) | 0.421a |
| Lawton I-ADL, median (IQR) | 7 (7–7) | 7 (7–7) | 7 (7–7) | 0.176b |
| Dependency in P-ADL, n (%) | 7 (10) | 7 (12) | 0 (0) | 0.205a |
| SAPS II,median (P25–75) | 24(15–37) | 29(21–39) | 7(0–13) | <0.001b |
| APACHE II, median (IQR) | 7(5–11) | 8(6–11) | 4(3–6) | <0.001b |
| AKI | 7 (10) | 6 (10) | 1(8) | 0.833a |
| Delirium | 17(24) | 17(29) | 0(0) | 0.025a |
| PACU length of stay (minutes), median (IQR) | 21 (19–57) | 21 (19–57) | 31 (20–60) | 0.501a |
| Hospital length of stay (days), median(IQR) | 10(7–15) | 11(7–16) | 8(7–11) | 0.034b |
| Mortality in PACU, n (%) | 3(4) | 3 (5) | 0 (0) | 0.421a |
| Mortality in hospital, n (%) | 5 (7) | 5 (9) | 0 (0) | 0.291a |
| Mortality at 6 months follow-up | 13(19) | 13(22) | 0(0) | 0.011a |
a Fisher’s exact test, b Mann-Whitney U test, IQR, interquartile range.
RCRI, Revised Cardiac Risk Index I-ADL, Instrumental Activities of Daily Living; P-ADL, Personal Activities of Daily Living; SAPS II, Simplified Acute Physiology Score, APACHE II Acute Physiology & Chronic Health Evaluation PACU, Post Anaesthesia Care Unit; IQR, interquartile range.
Veiga et al. BMC Anesthesiology 2013 13:4 doi:10.1186/1471-2253-13-4
